SBIR/STTR Research Award
Commercialization of automated mobile device for accurate comprehensive refraction
Award amount
$1,399,239Program and phase
SBIR · Phase IIAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PLENOPTIKA, INC.
- Proposal award date
- 2021-03-01
- Contract end date
- 2023-02-28
- UEI
- J6K8AE4B6935
- Solicitation number
- PAR19-335
- Topic code
- 100
Research abstract
Summary
The goal of this CRP SBIR application is to commercialize QuickSee Plus that was researched and
developed during SBIR Phase 2 work. QuickSee Plus, will be a unique tool for eye care professionals that
enables comprehensive refraction (objective and subjective) in a single, portable package. It will provide
tremendous value for eye care professionals as it improves their efficiency within the clinic and extends
their reach outside the clinic, thereby, greater accessibility to refractive eye care for health disparity
populations
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Improving access to vision correction for health disparity populations with the QuickSee: an accurate, low-cost, easy-to-use objective refractor
- Development of a low-cost, portable autorefractor for the measuring of refractive errors in low-resource settings
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Research funding history
3 SBIR/STTR records share this UEI (2015–2021). Reported award amounts total $1,873,643. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services